Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of Nivolumab in patients with metastatic clear cell Renal Cell Carcinoma (mccRCC)

Next Previous
Trial Profile

A phase II trial of Nivolumab in patients with metastatic clear cell Renal Cell Carcinoma (mccRCC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms CheckMate-010

Most Recent Events

  • 01 Aug 2023 Results by deriving data from JAVELIN Renal 101 and checkmate-009/010/025 and other studies; retrospectively analyzing the role of BAP1-score as a biologically and clinically significant predictor of immune microenvironment and the clinical benefits from ICI-based immunotherapies over angiogenic/mTOR inhibitors, demonstrating its potential utility in optimizing the personalized therapeutic strategies in patients with advanced ccRCC , published in the Cancer Immunology Immunotherapy
  • 10 Apr 2021 Results of retrospectively constructed and validated Multi-Omics Responder Scores in multiple public cohorts presented at the 112th Annual Meeting of the American Association for Cancer Research
  • 31 May 2020 Results, of pooled analysis of data from 3 prospective studies (CheckMate 009, CheckMate 010, CheckMate 025) assessing immunogenomic characterization of advanced clear cell renal cell carcinoma presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top